2. Academic Validation
  3. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)

Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)

  • J Med Chem. 2010 Apr 8;53(7):2779-96. doi: 10.1021/jm901488g.
Michael E Jung 1,  Samedy Ouk,  Dongwon Yoo,  Charles L Sawyers,  Charlie Chen,  Chris Tran,  John Wongvipat
Affiliations

Affiliation

  • 1 Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, USA. [email protected]
PMID: 20218717 DOI: 10.1021/jm901488g
Abstract

A structure-activity relationship study was carried out on a series of thiohydantoins and their analogues 14 which led to the discovery of 92 (MDV3100) as the clinical candidate for the treatment of hormone refractory prostate Cancer.

Figures
Products